Strides Shasun gets US health regulator tentative nod for HIV treatment drug
The company has received tentative approval from USFDA for Efavirenz tablets USP, 600 mg, Strides Shasun said in a regulatory filing.
NEW DELHI: Strides Shasun today said it has received tentative approval from the US health regulator for Efavirenz tablets used in treating human immunodeficiency virus (HIV) infection.The company has received tentative approval from the US Food and Drug Administration (USFDA) for Efavirenz tablets USP, 600 mg, Strides Shasun said in a regulatory filing.
The final approval will be received after patent expiry in August 2018, it added.
According to IMS sales data, the US market for Efavirenz tablets is around USD 150 million.
The company will manufacture the product at its oral dosage facility in Bengaluru.
The stock was 1.89 per cent higher at Rs 1,062 on BSE.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions